SCHEMBL25544720

SCHEMBL25544720

CSCCCCCCC(=O)NSC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 4/20 0.39
HDAC1 Q13547 4/20 0.39
HDAC2 Q92769 4/20 0.39
HDAC8 Q9BY41 4/20 0.39
HDAC6 Q9UBN7 4/20 0.39
HDAC5 Q9UQL6 4/20 0.39
HSP90AA1 P07900 1/20 0.38
FAAH O00519 4/20 0.36
HDAC4 P56524 3/20 0.36
HDAC7 Q8WUI4 3/20 0.36
HDAC10 Q969S8 3/20 0.36
HDAC11 Q96DB2 3/20 0.36
HDAC9 Q9UKV0 3/20 0.36
FOLH1 Q04609 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 1/20 0.34
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11171037 0.81 HSP90AA1 (0.59) HSP90AA1FAAHHDAC11ALDH1A1MEN1
SCHEMBL18971148 0.81 HSP90AA1 (0.59) HSP90AA1FAAHHDAC11ALDH1A1MEN1
SCHEMBL23640086 0.78 LMNA (0.54) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL20048668 0.78 HSP90AA1 (0.56) HSP90AA1FAAHHDAC11ALDH1A1MEN1
SCHEMBL14984428 0.78 FAAH (0.50) FAAHALDH1A1FNTAFNTB
SCHEMBL19634652 0.78 FAAH (0.64) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL24002308 0.76 KDM4C (0.45) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL24530510 0.76 FAAH (0.63) FAAHFOLH1MEN1MAPK1KMT2A
SCHEMBL6894821 0.76
SCHEMBL14012179 0.75 SELP (0.51) FAAHALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158150-A1 COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF NOVARTIS AG (CH) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158150-A1 COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF NSUN2, NSUN3, POLM HDAC3 3093/4885HDAC1 2995/4885HDAC2 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.